Brief: Coloplast Keeps FY 2025/26 Guidance Unchanged

Coloplast A/S

06/02/2026 06:40

Feb 6 (Reuters) - Coloplast A/S COLOb.CO:

COLOPLAST OUTLOOK FY ORGANIC GROWTH 7%

COLOPLAST Q1 REVENUE DKK 7,043 MILLION VERSUS. ESTIMATE DKK 7,181 MILLION

COLOPLAST Q1 EBIT MARGIN 26%

COLOPLAST Q1 EBIT DKK 1,815 MILLION VERSUS. ESTIMATE DKK 1,946 MILLION

COLOPLAST Q1 NET INCOME DKK 1,397 MILLION

COLOPLAST Q1 PRETAX PROFIT DKK 1,791 MILLION

FY 2025/26 GUIDANCE UNCHANGED

SIGNIFICANT UNCERTAINTY IN SKIN SUBSTITUTES MARKET IS EXPECTED TO CONTINUE THROUGHOUT YEAR.

LONG-TERM, KERECIS IS EXPECTED TO SEE CONTINUED STRENGTHENING OF ITS COMPETITIVE POSITION RELATIVE TO PEERS

Source text: ID:nGNE7CMqyf

Further company coverage: [COLOb.CO]

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))